In the randomized, double-blind, phase III ORIENT-12 study, 357 histologically or cytologically confirmed clinical stage IIIB to IV squamous NSCLC patients without EGFR-sensitive mutations or ALK rearrangements were enrolled and randomly assigned (1:1) to be administered either sintilimab plus GP (sintilimab group) or placebo plus GP (placebo group) [18]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.